AbbVie Declares Quarterly Dividend
Get Alerts ABBV Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.7%
Revenue Growth %: +8.8%
Join SI Premium – FREE
NORTH CHICAGO, Ill., Feb. 18, 2016 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.57 per share.
The cash dividend is payable May 16, 2016 to stockholders of record at the close of business on April 15, 2016.
Since the company's inception in 2013, AbbVie has increased its dividend by more than 42 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About AbbVieAbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abbvie-declares-quarterly-dividend-300222317.html
SOURCE AbbVie Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbbVie updates 2026 EPS guidance after $291M IPR&D charge
- Red Dot Award-Winning Donburi Container Reimagines Japanese Food Culture for Modern Lifestyles
- Prospect Markets to Enter US Prediction Markets Through Partnership backed by Crypto.com
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Twitter, Dividend, Dividend AristocratsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share